Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4123 Target Snapshot

Neurotensin receptor type 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,199Compounds
206Assays
1Approved Drugs
1,376.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Neurotensin receptor type 1 shows clinical signal disease relevance led by lung cancer. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P30989. Start with lung cancer, then reuse UniProt P30989 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with lung cancer, then reuse UniProt P30989 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
lung cancer

Neurotensin receptor type 1 shows clinical signal disease relevance led by lung cancer. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with lung cancer because it currently carries clinical signal support. Linked drugs include REMINERTANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neurotensin receptor type 1 as ChEMBL target CHEMBL4123, mapped to UniProt P30989. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neurotensin receptor type 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4123
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30989
Neurotensin receptor type 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neurotensin receptor type 1 is the right protein anchor across sources, using UniProt P30989 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why lung cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNeurotensin receptor type 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30989
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeurotensin receptor type 1
UniProt AccessionP30989
Component TypeProtein
Sequence Length418 aa

Neurotensin receptor type 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Neurotensin receptor type 1, mapped to UniProt P30989. Sequence length is 418 aa.

Mapped IDP30989
Review nameNeurotensin receptor type 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Neurotensin receptor type 1 shows clinical signal disease relevance led by lung cancer. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREMINERTANT
Clinical signal Phase II
lung neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREMINERTANT
Clinical signal Phase II
small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREMINERTANT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with lung cancer because it currently carries clinical signal support. Linked drugs include REMINERTANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaselung cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
3
Phase III
Assay Mix

Activity Type Distribution

IC50159.0
KI254.0
EC50926.0
KD37.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3622802 10.7 IC50 0.02 Preclinical
CHEMBL415788 10.38 EC50 0.0416 Preclinical
CHEMBL258221 10.1 IC50 0.08 Preclinical
CHEMBL415788 9.89 Ki 0.1288 Preclinical
CHEMBL2369722 9.85 IC50 0.14 Preclinical
CHEMBL342252 9.85 Ki 0.14 Preclinical
CHEMBL342252 9.8 Kd 0.16 Preclinical
CHEMBL407196 9.8 IC50 0.16 Preclinical
CHEMBL1791383 9.74 IC50 0.18 Preclinical
CHEMBL4593174 9.65 Ki 0.223 Preclinical
Distribution

pChEMBL Value Distribution

237
5.0
160
5.5
45
6.0
57
6.5
43
7.0
61
7.5
74
8.0
86
8.5
90
9.0
40
9.5
pChEMBL
Assay Landscape

Assay Landscape

206
Total Assays
454
Tested Compounds
3
Assay Types
Binding — 164 assays, 454 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 80 62 8.2
cell-based format 74 252 7.2
cell membrane format 7 20 7.8
assay format 2 114 5.6
organism-based format 1 6 8.5
Functional — 37 assays, 250 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 36 77 7.3
assay format 1 173 4.9
ADME — 5 assays, 33 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 33 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine